Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K, Form 10-Q and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.Esbriet® is a registered trademark of InterMune, Inc. 

Financial tables follow:InterMune, Inc.PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited, in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2012201120122011Revenue, net  Esbriet

$

7,534$

118

$

17,952$

118  Collaboration revenue-0-2,629Total revenue, net7,53411817,9522,747Costs and expenses:  Cost of goods sold2,0173856,200385  Research and development26,17517,04574,55353,967  Selling, general and administrative23,75423,65275,68062,661Total costs and expenses51,94641,082156,433117,013Loss from operations(44,412)(40,964)(138,481)(114,266)Interest income148131452390Interest expense(2,031)(1,281)(6,473)(4,154)Other income (expense)975(227)(149)(322)Loss from operations before income taxes(45,320)(42,341)(144,651)(118,352)Income tax expense192-326-Loss from continuing operations (45,512)(42,341)(144,977)(118,352)Discontinued operations:Income from discontinued operations1324,0972,1258,111Gain on sale of discontinued operations--51,335-Income from discontinued operations1324,09753,4608,111Net loss

$

(45,380)$

(38,244)

$

(91,517)$

(110,241)Basic and diluted net income (loss) per common share:Continu
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... A new way to produce engineered skin ... skin grafting technologies, it also speeds up the healing ... in the October issue of STEM CELLS Translational Medicine, ... that result from severe burns and chronic wounds. , ... elements. These wounds heal by contraction, with epithelization (the ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/22/2014)... 22, 2014 New test innovations will be ... diagnostic (IVD) test industry, especially as companies struggle with ... listed more than 25 testing innovations in important disease ... of IVD products. Kalorama details the new approaches its biennial ... for In Vitro Diagnostic Tests , 9th Edition ...
(Date:10/22/2014)... North American crystal oscillator market report defines and segments ... of revenue. This market was valued at $531.4 million ... by 2018, at a CAGR of 3.3% from 2013 ... North American crystal oscillator market report, to get an ... a glimpse of the segmentation of the market, and ...
Breaking Biology Technology:New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... ATLANTA and BOSTON, March 17 Alimera Sciences,and ... Xetra: PSI) today announced that,they have amended their ... companies, Phase III investigative treatment for,diabetic macular edema ... equity in the future profits of Medidur FA ...
... Validates Platform Designed to Deliver Electronic X-ray-Based, ... Minimally Shielded Clinical Settings, SUNNYVALE, Calif., ... it has received expanded clearance from the ... Axxent(R) Electronic Brachytherapy System, a,proprietary technology platform ...
... inflammation poised to ... control., MENLO PARK, Calif., March 17 Apieron, ... system has received,clearance to market by the U.S. Food ... exhaled nitric oxide (eNO), which is a,well-established indicator of ...
Cached Biology Technology:Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 3
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... major greenhouse gas carbon dioxide (CO2) from industrial plants ... is on the verge of becoming a commercial reality. Several ... U.S. are leading the way, according to an article in ... the American Chemical Society. Alex Scott, C&EN,s senior editor ...
... WEST BEND, Wis. , Nov. 6, 2013 ... organization focused on driving value for clients through technology and ... collaboration platform to help manage the execution of ... The Spaulding Clinical team is using ...
... squishy gel that when compressed like at a ... material could someday deliver medications when and where osteoarthritis ... ACS journal Biomacromolecules . Xinqiao Jia, Chandran ... few decades, researchers have been developing a variety of ...
Cached Biology News:Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines 2Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines 3
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse TrkC Affinity Purified Polyclonal Ab...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Biology Products: